HCA Healthcare, Inc. · HCA · FY2026 Q1 · Calendar Q2 2026

HCA maintains 2026 outlook as payments offset softer hospital volume

The supplied analysis supports a balanced view: HCA's demand and earnings trajectory remained resilient enough for management to maintain guidance, but the near-term evidence also shows reliance on Medicaid supplemental payments and cost initiatives to offset softer volume and payer-related pressure.

Reported Before market openNYSEHealthcare $94.50B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $7.15 Consensus $7.12
EPS surprise +0.4% Reported versus consensus
Reported revenue $19.11B Consensus $19.09B
Revenue surprise +0.1% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -8.8% Event window
SPY move +0.8% Same window
Abnormal move -9.5% Stock minus SPY
Volume 3.9× Versus trailing sessions
Subsequent drift -8.9% Up to 20 sessions
HCASPY benchmark

Ask FN2 about HCA FY2026 Q1

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The current analysis adds that temporary volume weakness was largely offset by stronger-than-expected Medicaid supplemental payments, while management expanded its AI agenda and continued network investment. The 2026 outlook remained unchanged, but Florida approval timing, exchange effects and resiliency savings remain unresolved.

Guidance delta

Management maintained 2026 guidance, including expected 2–3% volume growth for the remainder of the year.

Key takeaways

  • Management said a mild respiratory season and winter storms reduced volume temporarily.
  • Supplemental Medicaid payments largely offset the volume shortfall, including an unexpected $200 million full-year net benefit in the analysis.
  • Management highlighted AI tools, resiliency savings, network expansion and outpatient acquisitions.
  • Capital spending remains robust, with $1.1 billion in Q1 and a $5.5–$6 billion approved project pipeline.
  • The main debate is whether payment support and cost initiatives can offset payer-mix and exchange-related pressure.

Management priorities

  • Expand AI tools such as nurse handoff and ambient listening.
  • Advance hospital and outpatient network development.
  • Pursue urgent-care, ambulatory-surgery and freestanding-ER acquisitions.
  • Seek additional Medicaid supplemental approvals.
  • Continue resiliency-program cost-saving initiatives.

Follow HCA with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
HCA EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q1 '24 estimate $5.01 Q1 '24 actual $5.93, beat Q2 '24 estimate $4.85 Q2 '24 actual $5.53, beat Q3 '24 estimate $4.97 Q3 '24 actual $5.03, beat Q2 '25 estimate $6.29 Q2 '25 actual $6.84, beat Q3 '25 estimate $5.79 Q3 '25 actual $6.96, beat Q4 '25 estimate $7.46 Q4 '25 actual $8.01, beat Q1 '26 estimate $7.12 Q1 '26 actual $7.15, beat Q2 '26 estimate $7.56 Q2 '26 actual $7.59, beat Q3 '26 estimate $6.70 Q4 '26 estimate $8.03 Q1 '27 estimate $7.78 Q2 '27 estimate $8.10
Show 1 more >

Analyst Consensus ?

ConsensusBuy45 ratings
Bullish2862.2%
Neutral1533.3%
Bearish24.5%

Analyst 52W Price Targets

$426.98Current
$224Low
$399.23Average
$579High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 24, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Leerink Partners Outperform OutperformMaintainSep 18, 2026
RBC Capital Outperform OutperformMaintainSep 8, 2026
JP Morgan Neutral NeutralMaintainAug 20, 2026
Wells Fargo Equal Weight Equal WeightMaintainAug 3, 2026
Mizuho Outperform OutperformMaintainJul 28, 2026
Show 40 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $426.98. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BMO CapitalAnalyst unavailable$495$438.12 +15.9%Sep 22, 2026
Goldman SachsAnalyst unavailable$485$389.62 +13.6%Jul 28, 2026
UBSAnalyst unavailable$579$390.7 +35.6%Jul 27, 2026
Deutsche BankAnalyst unavailable$476$387.41 +11.5%Jul 27, 2026
Morgan StanleyAnalyst unavailable$380$388.48 -11.0%Jul 27, 2026
See 115 more

Track every rating change on HCA the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital infrastructure, HCA Healthcare operates numerous specialized outpatient facilities.…

Historical context

All HCA earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
COO The Cooper Companies, Inc. FY2026 Q3 · Calendar Q3 2026 +2.7% -14.7% CooperCompanies beats expectations as inventory reduction weighs on vision revenue
MDT Medtronic plc FY2027 Q1 · Calendar Q3 2026 +4.3% +1.5% Medtronic raises FY27 outlook as growth broadens across platforms

Latest beats and misses

Who reports next

Get the HCA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-24T18:00:58.090676+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-24T18:00:58.087543+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-24. For educational purposes only; not investment advice.